Diagnosis: Lichen sclerosus, also known as lichen sclerosus et atrophicus, balanitis xerotica obliterans (in men), and kraurosis vulvae (in women).
DisCussion
Lichen sclerosus is a chronic inflammatory mucocutaneous disorder of unknown etiology. Women are affected at least 6 times as often as men, and postmenopausal women and prepubertal girls are most commonly affected (1). Patients usually complain of pruritus or pain, especially if lesions affect anogenital areas. Clinically, women present with atrophic hypopigmented skin that encircles the vaginal and perirectal area "figure of eight." Lesions may have associated excoriations or purpura. Over time, scarring may result in fusion of the labia and narrowing of the introitus. In men, lesions usually involve the foreskin, glans, or coronal sulcus; involvement of perirectal skin is rare (2). Balanitis xerotica obliterans represents a subset of lichen sclerosus in which there is significant destructive inflammation associated with phimosis and urethral stenosis.
Additionally, extragenital lesions may occur and are most often seen on the upper trunk-the neck, shoulders, and inframammary area. These lesions are usually asymptomatic atrophic hypopigmented patches with follicular plugging.
Rarely, anogenital lichen sclerosus can be associated with secondary malignancies such as penile or vulvar non-human papillomavirus-associated squamous cell carcinoma (2). Alternatively, malignancies such as extramammary Paget's disease may masquerade as lichen sclerosus (3).
Etiology
The etiology of lichen sclerosus is unknown. The risk of autoimmune diseases such as vitiligo, thyroid disease, and morphea is increased with lichen sclerosus. Anecdotal case reports have linked spirochetes, specifically Borrelia afzelii (4) and Borrelia burgdorferi (5), to lichen sclerosus; however, the results have not been duplicated. 
Diagnosis
The diagnosis of anogenital lichen sclerosus can usually be made clinically; however, several inflammatory dermatoses can occur in the anogenital area: lichen planus, cicatricial pemphigoid, lichen simplex, morphea, and eczema. A biopsy is recommended for refractory, ulcerative, or nodular lesions (3). Ulceration may be a sign of malignant transformation. Histologically, lesions are characterized by an inflammatory Tcell infiltrate (clonal in approximately half of patients), sclerosis and thickening of the dermis, and epidermal atrophy (6).
Treatment
Potent topical corticosteroids (such as clobetasol propionate 0.05% ointment) remain the most common therapies utilized; however, several other therapeutics may be employed (Table) . Recently, a phase II trial evaluated the safety and efficacy of twice-daily application of topical tacrolimus ointment 0.1% (8). At 24 weeks, 43% of patients had total clearance of their lesions and 34% had partial clearance. Maximal responses were seen after 10 to 24 weeks of therapy. Finally, phototherapy in the form of psoralen and ultraviolet A light (PUVA) as well as ultraviolet A1 light are also useful for lichen sclerosus (9, 10).
